EU Bacterial STIs Reach Record Highs: What New Data Reveals for European Public Health

EU Bacterial STIs Reach Record Highs: What the New ECDC Data Reveals

Bacterial sexually transmitted infections have reached record levels across the European Union, according to surveillance data published by the European Centre for Disease Prevention and Control (ECDC) on 21 May 2026, covering the calendar year 2024. This EU STIs record high is being driven by sharp, sustained increases in gonorrhoea and syphilis, alongside widening gaps in testing and prevention across EU and EEA member states. The picture is not a one-off spike: it is the tenth consecutive year of rising transmission, and it now coincides with a second, more dangerous development, the spread of drug-resistant gonorrhoea.

EU Bacterial STIs Reach Record Highs: What New Data Reveals for European Public Health

For European citizens, healthcare providers and policymakers, the message is direct. Bacterial STIs Europe-wide are climbing faster than prevention systems can respond, and the antibiotics that keep gonorrhoea treatable are beginning to fail. This article sets out exactly what the ECDC report found, why it happened, who is most affected, and what you can do.

Gonorrhoea and Syphilis Drive the Record Rise in Europe

The core finding is stark. In 2024, gonorrhoea Europe cases reached 106,331, a 303% increase since 2015, according to the ECDC (2026). Syphilis Europe cases hit 45,577, more than doubling over the same period. Chlamydia remained the most frequently reported bacterial STI at 213,443 cases, with a further 3,490 cases of lymphogranuloma venereum (LGV) recorded.

These are not marginal fluctuations. A tripling of gonorrhoea in under a decade represents one of the most significant infectious disease trends in the EU outside of the pandemic period. As Bruno Ciancio, ECDC Head of Unit for Directly Transmitted and Vaccine-Preventable Diseases, put it: "Sexually transmitted infections have been on the rise for 10 years and reached record high levels in 2024."

The demographic pattern matters for anyone assessing their own risk. Men who have sex with men remain the most disproportionately affected group and show the steepest long-term increases in gonorrhoea and syphilis. At the same time, syphilis is rising among heterosexual populations, particularly women of reproductive age, a shift with serious consequences examined below.

The Underreported Angle: Congenital Syphilis and a Failing Antibiotic

The headline numbers hide the two developments that make this year's data genuinely alarming rather than simply large. Both are underreported, and together they form the real story for European public health.

First, congenital syphilis nearly doubled, rising from 78 cases in 2023 to 140 in 2024 across 14 reporting countries (ECDC, 2026). Congenital syphilis occurs when an infected pregnant woman passes the infection to her unborn child, and it can cause stillbirth, neonatal death, or lifelong disability. It is almost entirely preventable through a single antenatal blood test and timely antibiotic treatment. A near-doubling in one year signals that antenatal screening is not reaching every pregnant woman in the EU.

Second, and separately, the ECDC issued a formal warning on 16 July 2026 that drug-resistant gonorrhoea is on the rise in Europe. An increasing number of member states have detected gonococcal strains resistant to ceftriaxone, the first-line antibiotic used to treat the infection. The ECDC risk assessment covered 11 European countries, with EU member states including Austria, Croatia, Denmark, France, Germany, Ireland, the Netherlands, Spain and Sweden reporting cases. While early detections since 2022 were largely travel-associated and linked to importation from South-East Asia, the ECDC now reports growing evidence of domestic transmission within the EU/EEA over the past two years.

As Csaba Ködmön, an ECDC microbiology expert, warned: "Local transmission of ceftriaxone-resistant gonorrhoea in Europe is a warning sign we should not ignore." With an estimated 82 million gonorrhoea infections globally each year, the erosion of the last reliable oral-injectable treatment is a public health threat, not a theoretical one. In response, the ECDC published a dedicated response plan in July 2026 to control and manage multidrug-resistant (MDR) and extensively drug-resistant (XDR) gonorrhoea across Europe.

Why It Is Happening: Testing and Prevention Gaps Across the EU

Record STI numbers are the product of widening gaps in testing and prevention, not simply riskier behaviour. The single most striking structural failure is cost. According to the ECDC, 13 of 29 reporting countries still require patients to pay out-of-pocket costs for STI testing. When a routine gonorrhoea or syphilis test carries a fee, uptake falls, infections go undiagnosed, and transmission continues unchecked.

The ECDC identifies several interacting drivers behind the bacterial STIs Europe surge:

Testing accessibility: paywalls and limited clinic capacity suppress diagnosis in nearly half of reporting countries.
Post-pandemic behaviour changes: national STI prevention strategies have not been updated to reflect shifts in sexual behaviour since 2020.
Weak partner notification: when diagnosed patients' partners are not traced and treated, reinfection chains persist.
Antenatal screening gaps: not every pregnant woman is being screened and treated in time, feeding the congenital syphilis rise.

Crucially, higher case numbers partly reflect better and more testing in some countries, which is a good thing. But the ECDC is clear that improved detection alone does not explain a 303% gonorrhoea increase. Genuine transmission is rising, and the prevention infrastructure has not kept pace. For broader context on how EU institutions coordinate cross-border responses, see our health articles.

The Real-World Social Impact Across Europe

Behind the statistics are ordinary people and, increasingly, newborns. The near-doubling of congenital syphilis means that in 2024, at least 140 European babies were born having contracted a preventable, potentially fatal infection in the womb. These cases cluster disproportionately among women with limited access to antenatal care, including migrants, low-income households, and those in precarious housing, groups already at the margins of EU healthcare systems.

The burden also falls unevenly by geography and income. In the 13 countries where testing carries a fee, the people most likely to skip a test are those who can least afford one, entrenching health inequality. Young adults, who account for a large share of chlamydia and gonorrhoea diagnoses, face long waits at overstretched sexual health clinics in several member states. And for anyone infected with a ceftriaxone-resistant strain, the daily reality could become repeat clinic visits, alternative and less-tested antibiotics, and prolonged infectivity, an outcome that was almost unthinkable in Europe a decade ago. The financial dimension of stretched health budgets is something we track in our finance coverage.

Public Health Response and ECDC Recommendations

The ECDC has set out concrete guidance for EU member states. In January 2026 it issued guidance on the use of doxycycline for post-exposure prophylaxis (doxy-PEP), while explicitly advising against broad doxy-PEP use for gonorrhoea because of antimicrobial resistance risks. Its core recommendations for national governments are:

Remove financial barriers so STI testing is free or low-cost and widely accessible.
Strengthen antenatal syphilis screening to diagnose and treat every pregnant woman according to infection stage.
Update national prevention strategies to reflect post-pandemic behaviour.
Reinforce partner notification to break reinfection chains.
Expand antimicrobial susceptibility testing to detect and contain resistant gonorrhoea early.

The European Commission and member state health ministries now face a coordination challenge that no single country can solve alone, given how freely people, and infections, move across EU borders. You can read the primary data on the ECDC gonorrhoea portal and the wider policy context via the European Commission.

What EU Readers Should Do Now

Individual action remains one of the most effective tools against this trend. Practical, specific steps:

Get tested regularly if you have new or multiple partners, even without symptoms, as gonorrhoea and chlamydia are frequently asymptomatic. Many EU cities offer free or anonymous clinics.
If you are pregnant, confirm you have had a syphilis blood test early in your antenatal care, and ask again if you are unsure. This single test prevents congenital syphilis.
Use condoms consistently, the only barrier method that reduces bacterial STI transmission.
Complete your full antibiotic course and attend any follow-up, particularly given resistant gonorrhoea. Do not self-medicate with leftover antibiotics.
Notify partners if you test positive, so they can be treated and reinfection is avoided.

For ongoing EU public health analysis, follow Baba International.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

How high have bacterial STIs risen in the EU?

According to ECDC data published on 21 May 2026, bacterial STIs reached record levels in 2024. Gonorrhoea rose to 106,331 cases (up 303% since 2015), syphilis to 45,577 cases (more than doubling since 2015), and chlamydia remained the most common at 213,443 cases.

Is gonorrhoea becoming untreatable in Europe?

Not yet, but the ECDC warned on 16 July 2026 that ceftriaxone-resistant gonorrhoea is spreading, with domestic transmission now documented in several EU member states. Ceftriaxone is the first-line treatment, so resistance threatens future options. The ECDC has published a response plan to contain MDR and XDR strains.

Why is congenital syphilis increasing in the EU?

Congenital syphilis cases nearly doubled from 78 in 2023 to 140 in 2024 across 14 reporting countries, driven by gaps in antenatal screening. It is preventable with a routine blood test and timely antibiotic treatment during pregnancy.

Where can I get tested in the EU?

Most EU member states offer STI testing through public sexual health clinics, GPs, or specialist centres. However, the ECDC notes that 13 of 29 reporting countries still charge out-of-pocket fees, so check local provision. Testing is often free for pregnant women and higher-risk groups.